Corsair Pharma is a clinical-stage company focused on improving the delivery of established medicines to reduce treatment burden and to meaningfully improve patients’ daily lives.
The company is developing a transdermal treprostinil prodrug system for pulmonary arterial hypertension (PAH). Treprostinil is an established PAH therapy, but its use can be limited by the burden of existing delivery challenges. Corsair is applying its transdermal expertise to a well-characterized therapeutic pathway, with the goal of making treatment more practical for patients and clinicians.
Corsair’s team is advancing its lead program, the TRX-248 Transdermal System, through early clinical development, guided by decades of experience in drug delivery, transdermal product development, pharmaceutical R&D, regulatory strategy, GMP manufacturing, and commercialization.
Corsair is advancing the TRX-248 Transdermal System through early clinical development, with human data supporting continued evaluation of its transdermal approach.
